Prolonged Response with Enzalutamide in a Prostate Cancer Patient on Hemodialysis-Reference-Cited by-同舟云学术

Prolonged Response with Enzalutamide in a Prostate Cancer Patient on Hemodialysis

Published:2022-11-30 Issue:6 Volume:12 Page:1033-1035
ISSN:2667-7180
Container-title:Journal of Contemporary Medicine
language:en
Short-container-title:J Contemp Med

Author:

KAMA BAŞCI Özge¹^ORCID,EKİNCİ Ferhat²,AKDERE ATEŞ Gonca³^ORCID,ERDOĞAN Atike Pinar³,DİRİCAN Ahmet⁴^ORCID

Affiliation:

1. Balikesir State Hospital

2. Şırnak Devlet Hastanesi

3. MANISA CELAL BAYAR UNIVERSITY, SCHOOL OF MEDICINE

4. İZMİR EKONOMİ ÜNİVERSİTESİ, TIP FAKÜLTESİ

Abstract

Current therapies in oncology that offer a longer and better quality of life are leading to more cases where cancer and chronic diseases coexist. Enzalutamide, a second-generation anti-androgen agent, was approved by the US Food and Drug Administration (FDA) in 2012 for the treatment of metastatic castration-resistant prostate cancer (mCRPC). There is no series with many patients on the use of enzalutamide in patients with end-stage renal disease (ESRD). We present a patient diagnosed with mCRPC who was followed up with enzalutamide treatment for about 5 years after progression with docetaxel and who was on hemodialysis 3 days a week.

Publisher

Cagdas Tip Dergisi: Journal of Contemporary Medicine

Subject

General Medicine

Reference10 articles.

1. 1. Mottet N, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol [Internet]. 2021 Feb 1 [cited 2022 Aug 19];79(2):243–62. Available from: https://pubmed.ncbi.nlm.nih.gov/33172724/

2. 2. Seok Han K, Joon Hong S. Exponential Rise in Prostate-Specific Antigen (PSA) during Anti-Androgen Withdrawal Predicts PSA Flare after Docetaxel Chemotherapy in Patients with Castration-Resistant Prostate Cancer. Yonsei Med J [Internet]. 2015;56:368. Available from: http://dx.doi.org/10.3349/ymj.2015.56.2.368

3. 3. Takimoto T, Nakabori T, Osa A, Morita S, Terada H, Oseto S, et al. Tubular nephrotoxicity induced by docetaxel in non-small-cell lung cancer patients.

4. 4. Loriot Y, Fizazi K, De Bono JS, Forer D, Hirmand M, Scher HI. Enzalutamide in Castration-Resistant Prostate Cancer Patients With Visceral Disease in the Liver and/or Lung: Outcomes From the Randomized Controlled Phase 3 AFFIRM Trial Running title: Enzalutamide and visceral mets in AFFIRM.

5. 5. Schwartz GG. Prostate Cancer, Serum Parathyroid Hormone, and the Progression of Skeletal Metastases. Cancer Epidemiol Biomarkers Prev [Internet]. 2008 Mar 1 [cited 2022 Sep 13];17(3):478–83. Available from: https://aacrjournals.org/cebp/article/17/3/478/11031/Prostate-Cancer-Serum-Parathyroid-Hormone-and-the